Please login to the form below

Not currently logged in
Email:
Password:

Dr Paula Salmikangas joins NDA Group

Moves to the regulatory affairs consultancy from the Finnish Medicines Agency

Paula SalmikaUK-headquartered regulatory affairs consultancy the NDA Group has appointed Dr Paula Salmikangas as a director.

She is the former chair of the EMA’s Committee for Advanced Therapies and comes to NDA from the Finnish Medicines Agency, where she served as a research professor.

She has also served as an adjunct professor of biochemistry for the University of Helsinki since 2006.

Dr Werner Van den Eynde, VP of NDA’s Advisory Board, said: “I am very excited to welcome Dr Paula Salmikangas on board. With her experience in and in-depth knowledge of biopharmaceuticals and advanced therapies she will be able to add tremendous value to clients in these areas and help them to make new and promising medicines available to patients.”

Dr Salmikangas is the second recent senior appointment at NDA Group following the appointment of Dr Van den Eynde, who joined earlier this month as its new vice president.

25th September 2017

From: Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Spirit

We find the soul in the science, the humanity in the data, harnessing the power of creativity to deliver medical...

Latest intelligence

Market Shaping for Better Healthcare Decisions
82% of healthcare business professionals agreed that it is important to get market shaping right to achieve future brand success....
launch engagement
Launch engagement
How the pandemic is forcing a fresh focus on the human touch and fresh thinking about engagement...
Everything you need to know about patient groups and clinical trials
Patient advocacy groups (PAGs) and pharma/biopharma/biotech and MedTech industries are all working towards the same goal: to improve health outcomes. And as PAGs are key stakeholders in the clinical trial...